Skip to main content
. Author manuscript; available in PMC: 2015 Apr 15.
Published in final edited form as: Clin Cancer Res. 2014 Feb 13;20(8):2115–2125. doi: 10.1158/1078-0432.CCR-13-2221

Figure 6. TKI Treatment Reduces ERK1/2 Activation in Primary Breast Tumors and Response is Associated with RET Expression.

Figure 6

A. Immunohistochemistry of resected tumors demonstrating a representative RET-positive and RET-negative sample. B. Representative western blots showing a greater reduction in ERK1/2 activation and no effect on AKT activation with sunitinib treatment in a RET-positive tumor compared to a RET-negative tumor. Western blots for ERK1/2, p-ERK1/2, AKT, and p-AKT were performed on all 30 tumors with representative blots shown. C. Fresh primary human breast cancer tissue treated in vitro with sunitinib had a significant reduction in mean ERK1/2 activation relative to control treated tumor tissue. Patient matched normal breast tissue did not have reduced ERK1/2 activation with sunitinib treatment. ERK1/2 activation was quantified for all 30 tumors and matched normal breast tissue. D. The reduction in ERK1/2 activation in response to sunitinib treatment was significantly greater in RET expressing tumors. The p values calculated in C and D was performed using the Student’s t-test.